Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting GATA2 in prostate cancer with siRNA

ABSTRACT: Targeting GATA2 in prostate cancer with siRNA

PROVIDER: PRJNA613445 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Targeting GATA2 in prostate cancer with siRNA

Project description:We investigated the role of GATA2 in castration-resistant prostate cancer cells using GATA2 siRNA.

2025-03-15 | GSE147217 | GEO

GATA2 as a potential prostate cancer metastasis-driving gene

Project description:Metastatic prostate cancer (PCa) is a terminal disease and establishment of novel therapeutic strategy specifically targeting metastasis is critically required for its management. This study was aimed at identifying metastasis-driving genes which could potentially be therapeutic targets for metastatic prostate cancer. Integrative analysis of gene expression profiles from a pair of metastatic and non-metastatic prostate cancer tissue xenografts was used to identify potential prostate cancer metastasis-driving genes. Among the candidate genes found, GATA2, a master regulator gene in the development of hematopoietic system, was particularly interesting since it is an important pioneer factor in the regulation of AR-target gene in prostate cancer. In consistent with our finding, elevated expression of the GATA2 gene in metastatic prostate cancers was found and its expression was significantly correlated with poor prognosis in prostate cancer patients. Furthermore, indication of the GATA2 gene maybe the metastasis-driving gene was evidenced in decreased of cell migration, tissue invasion and focal adhesion disassembly in GATA2-down-regulated LNCaP cells. Global gene expression analysis after silencing of the GATA2 gene revealed a significant changed in cell transcriptomes with ~ 2500 genes with > 2 fold mRNA level changed and FDR <0.05, indicates that GATA2 plays a critical role in cell reprogramming as pioneer factor in the development of prostate cancer metastasis. LNCaP human prostate cancer cells transiently knockdown with siRNA that specifically targeting GATA2 (siGATA2) or scrambled siRNA (sicontrol). RNAs were isolated from cells after 72 hours of incubation. Gene expression profiles of four biological replicates from each sample group were analyzed to identify differentially regulated downstream genes after knockdown of GATA2.

2014-01-20 | E-GEOD-49342 | biostudies-arrayexpress

Targeting GATA2 in prostate cancer with K11706 (1)

Project description:Targeting GATA2 in prostate cancer with K11706 (1)

| PRJNA613260 | ENA

Targeting GATA2 in prostate cancer with dilazep (2)

Project description:Targeting GATA2 in prostate cancer with dilazep (2)

| PRJNA613446 | ENA

Targeting GATA2 in prostate cancer with K11706 (2)

Project description:Targeting GATA2 in prostate cancer with K11706 (2)

| PRJNA613447 | ENA

Targeting GATA2 in prostate cancer with dilazep (1)

Project description:Targeting GATA2 in prostate cancer with dilazep (1)

| PRJNA613263 | ENA

Targeting AR in prostate cancer with siRNA

Project description:Targeting AR in prostate cancer with siRNA

| PRJNA613444 | ENA

Prostate cancer cell lines: non-targeting siRNA versus SChLAP1-siRNA treated

Project description:SChLAP1 is a novel long non-coding RNA expressed in prostate cancer. Here we performed transcriptional profiling of the prostate cancer cell lines LNCaP and 22Rv1 comparing non-targeting siRNA treatment versus SChLAP1-siRNA treatment. Goal was to determine the effect of SChLAP1 knockdown on gene expression in prostate cancer. Two-condition experiment: non-targeting siRNA versus SChLAP1 siRNA treated cells. Biological replicates: 1 control replicate, 2 treatment replicates. Technical replicates: 3 replicates per SChLAP1 siRNA. Cell lines: 22Rv1 and LNCaP.

2013-07-20 | E-GEOD-40383 | biostudies-arrayexpress

Prostate cancer cell lines: non-targeting siRNA versus SChLAP1-siRNA treated

2013-07-20 | GSE40383 | GEO

Targeting GATA2 in prostate cancer with K11706 (2)

Project description:We investigated the role of GATA2 in prostate cancer cells beyond the AR signaling axis, and characterized the pharmacological potency of the GATA2 small molecule inhibitor (SMI) K-11706 against prostate cancer cells. K-11706, which inhibited the proliferation and invasive behavior of PC cells, and dramatically reduced the genome-wide transcriptional activity of GATA2, AR, and cMyc, leading to downregulation of several prostate cancer drivers and AR/cMyc effector genes, notably FOXM1, EZH2, and CENPF. Transcriptional profiling and functional pathway analysis of the K-11706 transcriptomic footprint against curated databases delineated a biological network composed of genes involved in cell cycle/proliferation, stemness, metastasis and DNA repair.

2025-03-15 | GSE147214 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data